Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorecivivint Long-Term Extension Study in Knee Osteoarthritis
NCT04520607Phase 3Terminated
- Sponsor
- Biosplice Therapeutics
- Start
- Aug 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lorecivivint in osteoarthritis (OA), sponsored by Biosplice Therapeutics. Started Aug 2020; status: terminated.
02
Drugs
lorecivivint
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04520607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520607.